In 493 patients with nonmetastatic pancreatic ductal adenocarcinoma, a median overall survival (OS) of 54.4 months was found with mFOLFIRINOX, compared with 35.0 months with gemcitabine. With an OS over 20 months longer than the standard of care, this treatment regimen also reduced the risk of death by 36%. Read more . . .
In results of the PRODIGE 24/CCTG PA.6 trial presented at the 2018 ASCO Annual Meeting and again at the World Congress on Gastrointestinal Cancers, a modified FOLFIRINOX (mFOLFIRINOX) regimen was superior to the standard of care, gemcitabine, as postoperative therapy in patients with resected pancreatic cancer.